IJCS | Volume 31, Nº3, Maio / Junho 2018

311 1. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129(11):925-31. PMID: 9867744. 2. Merryweather-Clarke AT, Pointon JJ, Sherman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34(4):275-8. PMID: 9138148. 3. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis andmanagement of hemochromatosis: practice guidelines by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-43. doi: 10.1002/hep.24330. 4. Gulati V, Harikrishnan P, Palaniswamy C, Aronow WS, Jain D, Frishman WH. Cardiac involvement in hemochromatosis. Cardiol Rev. 2014;22(2):56-68. doi: 10.1097/CRD.0b013e3182a67805. 5. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy, better understanding of an increasing disorder. 
J Am Coll Cardiol. 2010;56(13):1001-12. doi:10.1016/j.jacc.2010.03.083. 6. Martinelli AL. Hemocromatose hereditaria: muito alem do HFE. In: Programa de Educação Médica Continuada. São Paulo: Sociedade Brasileira de Hepatologia. s.d. p. 1-8. 7. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124(20):2253-63. doi: 10.1161/ CIRCULATIONAHA.111.050773. Referências Iglesias et al. Hemocromatose: causa de insuficiência cardíaca International Journal of Cardiovascular Sciences. 2018;31(3)308-311 Relato de Caso